| Total sample | HIV-neg | HIV-U | HIV-D | p |
---|---|---|---|---|---|
n | 31 | 12 | 11 | 8 | Â |
Mean age (SEM) | 61.7 (1.28) | 61.7 (2.10) | 62.8 (2.19) | 60.1 (2.57) | 0.7302 |
Male gender, n (%)a | 15 (48%) | 7 (58%) | 2 (18%) | 6 (75%) | 0.0340 |
APOE \(\upvarepsilon\)4, n (%)b | 16 (52%) | 3 (25%) | 6 (55%) | 7 (88%) | 0.0227 |
APOE \(\upvarepsilon\)2, n (%) | 3 (9.7%) | 2 (17%) | 0 | 1 (13%) | 0.3825 |
Mean area diffuse plaque, um2 (SEM) | 2495 (310) | 2213 (503) | 2350 (526) | 3115 (617) | 0.5054 |
Mean area cored plaque, um2 (SEM)* | 1560 (94) | 1548 (159) | 1649 (159) | 1445 (194) | 0.6383 |
cored plaques | |||||
GFAP plaque | 0.7174 [0.1098,1.2907] | 0.1126 [0.0305,1.2316] | 1.0813 [0.6481,1.2491] | 0.2959 [0.0000,1.4296] | 0.3433 |
GFAP rim | 0.4148 [0.0736,0.9678] | 0.0885 [0.0239,0.9515] | 0.6775 [0.4148,0.9360] | 0.2008 [0.0268,1.0748] | 0.2997 |
CD68 plaque | 0.7098 [0.1445,1.0210] | 0.8035 [0.0993,1.0601] | 0.8004 [0.3006,1.0100] | 0.4198 [0.1282,1.2166] | 0.8655 |
CD68 rim | 0.1570 [0.6844,0.1780] | 0.1632 [0.0649,0.1964] | 0.1313 [0.0797,0.1766] | 0.1146 [0.0494,0.2480] | 0.8947 |
Iba1 plaque | 0.9427 (0.0810) | 0.9651 (0.1383) | 0.9425 (0.1383) | 0.9093 (0.1694) | 0.9681 |
Iba1 rim | 0.5612 (0.0504) | 0.6003 (0.0845) | 0.5761 (0.0845) | 0.4800 (0.1034) | 0.6554 |
diffuse plaques | |||||
GFAP plaque | 0.4327 [0.0592,0.8564] | 0.1513 [0.0394,0.9381] | 0.6198 [0.0969,0.7264] | 0.3205 [0.1084,0.8807] | 0.4226 |
GFAP rim | 0.3135 [0.0558,0.6165] | 0.1392 [0.0509,0.6278] | 0.4609 [0.0781,0.6165] | 0.3612 [0.0763,0.7271] | 0.5281 |
CD68 plaque | 0.1682 [0.0931,0.3177] | 0.1478 [0.1027,0.2158] | 0.1970 [0.0641,0.3547] | 0.2592 [0.0664,0.3815] | 0.6105 |
CD68 rim | 0.1492 [0.1099,0.1673] | 0.1444 [0.1097,0.1937] | 0.1489 [0.1086,0.1673] | 0.1576 [0.1257,0.2428] | 0.5010 |
Iba1 plaque | 0.7593 (0.0602) | 0.7855 (0.0994) | 0.7077 (0.1038) | 0.7906 (0.1217) | 0.8269 |
Iba1 rim | 0.5970 (0.0452) | 0.6353 (0.0745) | 0.5556 (0.0779) | 0.5965 (0.0913) | 0.7626 |